Guillain-Barre Syndrome (GBS)

Clinical guidelines for managing acute inflammatory demyelinating polyneuropathy, IVIG, and plasmapheresis.

⏱️ 5 min read

Table of Contents

🧠 Standard of Care & Diagnosis

Guillain-BarrΓ© Syndrome (GBS) is a rare, rapid-onset autoimmune disorder where the body's immune system attacks the peripheral nervous system. This causes rapidly ascending muscle weakness and paralysis, usually starting in the legs and moving upward.

πŸ’Š Acute Medical Therapies

Treatment must be initiated as quickly as possible (ideally within the first 1 to 2 weeks of symptom onset) to truncate the immune attack and prevent irreversible nerve damage. Interestingly, systemic corticosteroids are not effective for GBS.

Intravenous Immunoglobulin (IVIG)

This is the most common first-line treatment. High doses of healthy antibodies (immunoglobulins) derived from thousands of blood donors are infused directly into the patient's vein over several days. These healthy antibodies essentially neutralize and overwhelm the pathogenic antibodies causing the nerve damage.

Plasmapheresis (Plasma Exchange)

If IVIG is contraindicated or ineffective, plasmapheresis is used. The patient's blood is routed through a machine that separates the plasma (which contains the harmful antibodies) from the blood cells. The cells are then mixed with replacement fluids and returned to the body, actively washing out the autoimmune threat.

πŸ₯ Critical Care & Rehabilitation

Because GBS can cause rapid respiratory failure and severe autonomic dysfunction (wild fluctuations in heart rate and blood pressure), patients are heavily monitored, usually in an Intensive Care Unit (ICU).

πŸ”¬ Active Clinical Trials

Current research focuses on optimizing critical care protocols and investigating genetic predispositions following viral exposures.

Important: Deep dive into actively recruiting trials in our comprehensive Clinical Trials Catalogue to find studies you may qualify for.

πŸ—ΊοΈ Next Steps After Diagnosis

A GBS diagnosis is terrifying due to its rapid onset, but it is highly treatable. If you or a loved one has just been diagnosed:

  1. Advocate for Immediate Treatment: Do not "wait and see." IVIG or plasmapheresis must be started as soon as possible after diagnosis to blunt the severity of the nerve damage. Ask the care team directly about the timeline for initiating these therapies.
  2. Prepare for the ICU: Because GBS can paralyze the diaphragm suddenly, patients are often transferred to the ICU for constant respiratory monitoring (via frequent forced vital capacity/FVC breathing tests). Do not panic if intubation is required; it is a temporary, life-saving measure to let the body rest while the IVIG works.
  3. Prevent Secondary Complications: While paralyzed in the hospital bed, the patient is at extreme risk for blood clots (DVT) and pressure ulcers. Ensure the nursing team is implementing aggressive DVT prophylaxis (like sequential compression devices) and turning the patient every 2 hours.
  4. Aggressive Rehabilitation: Once the disease stabilizes and the patient is medically cleared, demand an immediate transfer to an acute inpatient rehabilitation facility. You must push the recovering nerves to rewire themselves through intense, daily physical therapy.

❓ Patient FAQ

Q: Will I fully recover from GBS?
A: Most patients (about 70-80%) eventually make a full or near-full recovery and can walk independently again six months after onset. However, about 20% suffer from significant permanent residual weakness or severe fatigue.

Q: Can I get GBS again?
A: The recurrence rate of classic GBS is very low (less than 5%). If symptoms continue to fluctuate or return repeatedly over months, the diagnosis may be revised to Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Get the Free 2026 Clinical AI Directory

Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.

Request Directory via Email

Was this guide helpful?